Why Tempest Therapeutics (TPST) Stock Is Down 45% Today

Benzinga11-20

Tempest Therapeutics Inc (NASDAQ:TPST) shares are trading sharply lower Wednesday morning following the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. Here’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584925771?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/19/Stock-Market-Trading-Graph-And-Financial.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2025-11-20 00:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584925771","market":"nz","top_or_hot":-1,"title":"Why Tempest Therapeutics (TPST) Stock Is Down 45% Today","media":"Benzinga","content":"<div>\n<p>Tempest Therapeutics Inc (NASDAQ:TPST) shares are trading sharply lower Wednesday morning following the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. Here’s ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/25/11/48954607/why-tempest-therapeutics-tpst-stock-is-down-45-today\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Tempest Therapeutics (TPST) Stock Is Down 45% Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Tempest Therapeutics (TPST) Stock Is Down 45% Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-20 00:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/25/11/48954607/why-tempest-therapeutics-tpst-stock-is-down-45-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tempest Therapeutics Inc (NASDAQ:TPST) shares are trading sharply lower Wednesday morning following the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. Here’s ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/25/11/48954607/why-tempest-therapeutics-tpst-stock-is-down-45-today\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TPST","symbol_name":"Tempest Therapeutics Inc.","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/11/48954607/why-tempest-therapeutics-tpst-stock-is-down-45-today","article_id":"2584925771","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/19/Stock-Market-Trading-Graph-And-Financial.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/25/11/48954607/why-tempest-therapeutics-tpst-stock-is-down-45-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584925771","pubTimestamp":1763569980,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TPST":"Tempest Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"为什么Tempest Therapeutics(TPST)股价今天下跌45%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TPST":1.5},"content_text":"Tempest Therapeutics Inc (NASDAQ:TPST) shares are trading sharply lower Wednesday morning following the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. Here’s what investors need to know.\nWhat To Know: While the deal expands Tempest’s pipeline, the market is reacting negatively to significant shareholder dilution. Tempest will issue roughly 8.27 million new shares to Factor, equivalent to 65% of the company's outstanding stock. To mitigate this, existing shareholders will receive warrants exercisable at $18.48 per share.\nThe transaction creates a leadership shakeup, with Factor co-founder Dr. Matt Angel set to replace Stephen Brady as CEO upon the deal’s expected closing in early 2026. \nStrategically, Tempest gains the clinical-stage TPST-2003 program and projects that the deal, alongside new investment commitments, will extend its cash runway into mid-2027.\nBenzinga Edge Rankings: Benzinga Edge data currently assigns the stock bearish signals flashing across its short, medium and long-term price trends.\nTPST Price Action: Tempest Therapeutics shares were down 50% at $4.60 at the time of publication on Wednesday. The stock is trading near its 52-week low of $4.95, according to Benzinga Pro data.\nRead Also: EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants\nBesides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. \nFor example, in Tempest Therapeutics’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.\nImage: Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584925771","isCrawlerRequest":true}